Carisma Therapeutics Inc. (CARM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carisma Therapeutics Inc. (CARM) has a cash flow conversion efficiency ratio of -2.201x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.91 Million) by net assets ($-867.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Carisma Therapeutics Inc. net asset quality index to measure how much of total assets are equity-financed.
Carisma Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Carisma Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Carisma Therapeutics Inc. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Carisma Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carisma Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fibra Mty S.A.P.I. de C.V.
MX:FMTY14
|
0.045x |
|
GenIP PLC
LSE:GNIP
|
-0.432x |
|
Ordinary Fully Paid Deferred Settlement
AU:HRZDB
|
-0.180x |
|
Sabien Technology Group Plc
LSE:SNT
|
-0.634x |
|
Sorted Group Holdings Plc
LSE:SORT
|
1.476x |
|
SCG PACKAGING -FGN- BA 1
F:5Y7A
|
0.039x |
|
AdCapital AG
F:ADC
|
N/A |
|
musicMagpie PLC
LSE:MMAG
|
0.302x |
Annual Cash Flow Conversion Efficiency for Carisma Therapeutics Inc. (2011–2024)
The table below shows the annual cash flow conversion efficiency of Carisma Therapeutics Inc. from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Carisma Therapeutics Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-27.91 Million | $-59.92 Million | 2.147x | +170.17% |
| 2023-12-31 | $26.53 Million | $-81.18 Million | -3.060x | -5869.38% |
| 2022-12-31 | $-142.67 Million | $-7.57 Million | 0.053x | +124.39% |
| 2021-12-31 | $171.71 Million | $-37.33 Million | -0.217x | -107.43% |
| 2020-12-31 | $-9.23 Million | $-27.01 Million | 2.927x | +108.32% |
| 2019-12-31 | $-26.70 Million | $-37.52 Million | 1.405x | +372.12% |
| 2018-12-31 | $44.21 Million | $-22.83 Million | -0.516x | +47.58% |
| 2017-12-31 | $18.03 Million | $-17.77 Million | -0.985x | -1553.09% |
| 2016-12-31 | $38.68 Million | $2.62 Million | 0.068x | +103.72% |
| 2015-12-31 | $18.94 Million | $-34.53 Million | -1.823x | -129.03% |
| 2014-12-31 | $36.83 Million | $-29.31 Million | -0.796x | +86.16% |
| 2013-12-31 | $2.35 Million | $-13.49 Million | -5.752x | -72.90% |
| 2012-12-31 | $5.74 Million | $-19.09 Million | -3.327x | -104.50% |
| 2011-12-31 | $-147.00K | $-10.87 Million | 73.939x | -- |
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more